Pharmacokinetic and Pharmacodynamic Analyses of Drug-Drug Interactions between Iguratimod and Warfarin-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Analyses of Drug-Drug Interactions between Iguratimod and Warfarin

Published:2016-06-01 Issue:6 Volume:136 Page:905-911
ISSN:0031-6903
Container-title:YAKUGAKU ZASSHI
language:en
Short-container-title:YAKUGAKU ZASSHI

Author:

Yamamoto Tetsuya¹,Hasegawa Kyoko¹,Onoda Makoto¹,Tanaka Keiichi¹

Affiliation:

1. Research Laboratories, Toyama Chemical Co., Ltd.

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/yakushi/136/6/136_15-00261/_pdf

Reference13 articles.

1. 1) Tanaka K., Yamaguchi T., Nippon Yakurigaku Zasshi, 140, 285-292 (2012).

2. 2) Hara M., Abe T., Sugawara S., Mizushima Y., Hoshi K., Irimajiri S., Hashimoto H., Yoshino S., Matsui N., Nobunaga M., Mod. Rheumatol., 17, 10-16 (2007).

3. 3) Ishiguro N., Yamamoto K., Katayama K., Kondo M., Sumida T., Mimori T., Soen S., Nagai K., Yamaguchi T., Hara M.; Iguratimod-Clinical Study Group, Mod. Rheumatol., 23, 430-439 (2013).

4. 4) Tanaka K., Yamaguchi T., Hara M., Expert Rev. Clin. Immunol., 11, 565-573 (2015).

5. 5) Ministry of Health, Lobour, and Welfare, “Careram^® Tablets 25 mg; KOLBET^® Tablets 25 mg (Iguratimod)—Risk of severe haemorrhages by a suspected interaction with warfarin,” Blue letter, May 2013.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of High Altitude Environment on Pharmacokinetic and Pharmacodynamic of Warfarin in Rats;Current Drug Metabolism;2024-01

2. Iguratimod reduces B-cell secretion of immunoglobulin to play a protective role in interstitial lung disease;International Immunopharmacology;2021-08

3. Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis;Zeitschrift für Rheumatologie;2020-12-21

4. Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology;Bone Research;2019-09-03

5. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients;Modern Rheumatology;2018-07-23